晚期上皮性卵巢癌中种族与年龄的预后意义:一项NRG肿瘤学/妇科肿瘤组研究
70岁及以上女性死亡风险较60岁以下女性增加34%(HR=1.34;95%CI 1.16-1.54)。非西班牙裔黑人女性维持贝伐珠单抗治疗死亡风险降低54%(HR=0.46,95%CI 0.26-0.83),亚裔女性死亡风险较非西班牙裔白人降低27%(HR=0.73;95%CI 0.59-0.90),但组间总生存差异未达统计学显著。
要点
- 70岁及以上晚期卵巢癌女性死亡风险较60岁以下女性增加34%(HR=1.34;95%CI 1.16-1.54)。
- 非西班牙裔黑人女性加用维持贝伐珠单抗后死亡风险降低54%(HR=0.46,95%CI 0.26-0.83)。
- 亚裔女性较非西班牙裔白人死亡风险降低27%(HR=0.73;95%CI 0.59-0.90),但组间总生存差异未达统计学显著。
核心结论
- 非西班牙裔黑人女性加用贝伐珠单抗后死亡风险降低,亚裔患者死亡风险低于其他少数族裔群体,但这些临床上有意义的改善在组间总生存中未达统计学显著差异。
研究设计与样本
- 采用Cox比例风险模型评估年龄和种族/民族与总生存的关系。
- 研究人群中含280例少数族裔女性和328例70岁以上女性。
主要发现
- 70岁及以上女性较60岁以下女性死亡风险增加34%(HR=1.34;95%CI 1.16-1.54)。
- 非西班牙裔黑人女性加用维持贝伐珠单抗后死亡风险降低54%(HR=0.46,95%CI 0.26-0.83)。
- 亚裔女性较非西班牙裔白人死亡风险降低27%(HR=0.73;95%CI 0.59-0.90)。
- 亚裔女性血液学3级或以上不良事件较多。
- 尽管有上述临床上有意义的改善,组间总生存差异未达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy. METHODS: Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants. RESULTS: One-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90). CONCLUSIONS: Non-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.
引用
- duPont NC, Enserro D, Brady MF, et al. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2021. PMID: 34857397. doi:10.1016/j.ygyno.2021.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。